

# Xiaoxiang Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3544864/publications.pdf>

Version: 2024-02-01

20  
papers

328  
citations

933447

10  
h-index

839539

18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

650  
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. <i>Journal of Ovarian Research</i> , 2021, 14, 68.	3.0	6
2	Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 724620.	2.8	3
3	High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 761960.	2.8	6
4	&lt;p&gt;Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 11085-11093.	1.9	8
5	The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial. <i>Journal of Ovarian Research</i> , 2020, 13, 70.	3.0	1
6	Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. <i>Journal of Ovarian Research</i> , 2020, 13, 29.	3.0	4
7	Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. <i>Journal of Ovarian Research</i> , 2019, 12, 117.	3.0	17
8	No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case&acirc;control investigation. <i>European Journal of Medical Research</i> , 2018, 23, 47.	2.2	9
9	The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage III&acirc;IV high-grade serous ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 451-458.	1.7	32
10	Age is associated with prognosis in serous ovarian carcinoma. <i>Journal of Ovarian Research</i> , 2017, 10, 36.	3.0	28
11	Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 85.	3.0	10
12	CA-125&acirc;indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. <i>Journal of Ovarian Research</i> , 2013, 6, 14.	3.0	22
13	Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. <i>Human Pathology</i> , 2013, 44, 2373-2384.	2.0	50
14	Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women. <i>Breast</i> , 2013, 22, 707-712.	2.2	22
15	Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 61.	8.6	12
16	The significance of the alteration of 8-OHdG in serous ovarian carcinoma. <i>Journal of Ovarian Research</i> , 2013, 6, 74.	3.0	31
17	Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2013, 6, 31.	3.0	17
18	CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 815-822.	2.5	32

#	ARTICLE	IF	CITATIONS
19	Functional Polymorphisms of the hOGG1 Gene Confer Risk to Type 2 Epithelial Ovarian Cancer in Chinese. International Journal of Gynecological Cancer, 2011, 21, 1407-1413.	2.5	10
20	Two functional variations in 5'UTR of hOGG1 gene associated with the risk of breast cancer in Chinese. Breast Cancer Research and Treatment, 2011, 127, 795-803.	2.5	8